Skip to main content

Table 2 Characteristics of exposure to DMARDs during follow up among 71 patients with early RA

From: Immune response profiling in early rheumatoid arthritis: discovery of a novel interaction of treatment response with viral immunity

Medication Baseline Follow up
Prior to baseline Prescribed at baseline visit Cumulative exposure Taking at follow-up visit
Methotrexate 14 (20%) 49 (69%) 51 (72%) 50 (70%)
Hydroxychloroquine 8 (11%) 24 (34%) 44 (39%) 28 (39%)
Combination DMARD 5 (7%) 10 (14%) 17 (24%) 16 (23%)
Prednisone 16 (23%) 46 (65%) 49 (69%) 29 (41%)
Dose, mean ± SD   17.4 ± 14.2   6.7 ± 5.6
Median (minimum, maximum)   10.0 (5, 75)   5 (1, 25)
  1. Medications prescribed at the baseline visit include initiation within 2 weeks after baseline. DMARD, disease-modifying antirheumatic drug.